Zymogenetics, Inc.

George Robert Mabry, Iii

Scott R Presnell

Stephen R Jaspers

Debra G Gilbertson

Steven D Levin

Pallavur V Sivakumar

Yue Yao

Katherine E Lewis

Monica J Huber

Eugene C Yi

Marshall D Snavely

Disclosed are antagonists of PDGF receptor &#x3b2; (PDGFR&#x3b2;) and VEGF-A, including neutralizing anti-PDGFR&#x3b2; and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR&#x3b2; and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR&#x3b2; and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR&#x3b2; and/or VEGF-A antagonist.

Compositions and methods for inhibiting PDGFRbeta and VEGF-A

Compositions and methods for inhibiting PDGFR&#x3b2; and VEGF-A

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19

Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Growing community of inventors

Seattle, WA, United States of America

George Robert Mabry, Iii